vs
Side-by-side financial comparison of Hubbell Incorporated (HUBB) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.5B, roughly 1.6× Hubbell Incorporated). Zoetis runs the higher net margin — 25.3% vs 14.6%, a 10.7% gap on every dollar of revenue. On growth, Hubbell Incorporated posted the faster year-over-year revenue change (11.9% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $388.8M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 3.3%).
Hubbell Incorporated, headquartered in Shelton, Connecticut, is an American company that designs, manufactures, and sells electrical and electronic products for non-residential and residential construction, industrial, and utility applications. Hubbell was founded by Harvey Hubbell as a proprietorship in 1888, and was incorporated in Connecticut in 1905.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
HUBB vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.4B |
| Net Profit | $217.7M | $603.0M |
| Gross Margin | 34.6% | 70.2% |
| Operating Margin | 20.3% | 31.9% |
| Net Margin | 14.6% | 25.3% |
| Revenue YoY | 11.9% | 3.0% |
| Net Profit YoY | 10.5% | 3.8% |
| EPS (diluted) | $4.06 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.5B | $2.4B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.4B | $2.4B | ||
| Q2 24 | $1.5B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $217.7M | $603.0M | ||
| Q3 25 | $255.5M | $721.0M | ||
| Q2 25 | $244.2M | $718.0M | ||
| Q1 25 | $169.7M | $631.0M | ||
| Q4 24 | $197.0M | $581.0M | ||
| Q3 24 | $219.4M | $682.0M | ||
| Q2 24 | $213.6M | $624.0M | ||
| Q1 24 | $147.8M | $599.0M |
| Q4 25 | 34.6% | 70.2% | ||
| Q3 25 | 36.2% | 71.5% | ||
| Q2 25 | 37.2% | 73.6% | ||
| Q1 25 | 33.1% | 72.0% | ||
| Q4 24 | 33.8% | 69.5% | ||
| Q3 24 | 34.5% | 70.6% | ||
| Q2 24 | 35.0% | 71.7% | ||
| Q1 24 | 32.0% | 70.6% |
| Q4 25 | 20.3% | 31.9% | ||
| Q3 25 | 22.0% | 37.0% | ||
| Q2 25 | 22.7% | 36.7% | ||
| Q1 25 | 17.5% | 36.5% | ||
| Q4 24 | 19.3% | 31.6% | ||
| Q3 24 | 21.1% | 36.6% | ||
| Q2 24 | 20.7% | 33.0% | ||
| Q1 24 | 16.3% | 34.1% |
| Q4 25 | 14.6% | 25.3% | ||
| Q3 25 | 17.0% | 30.0% | ||
| Q2 25 | 16.5% | 29.2% | ||
| Q1 25 | 12.4% | 28.4% | ||
| Q4 24 | 14.8% | 25.1% | ||
| Q3 24 | 15.2% | 28.6% | ||
| Q2 24 | 14.7% | 26.4% | ||
| Q1 24 | 10.6% | 27.4% |
| Q4 25 | $4.06 | $1.37 | ||
| Q3 25 | $4.77 | $1.63 | ||
| Q2 25 | $4.56 | $1.61 | ||
| Q1 25 | $3.15 | $1.41 | ||
| Q4 24 | $3.65 | $1.29 | ||
| Q3 24 | $4.05 | $1.50 | ||
| Q2 24 | $3.94 | $1.37 | ||
| Q1 24 | $2.73 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.8B | $3.3B |
| Total Assets | $8.2B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.9M | — | ||
| Q3 25 | $680.9M | $2.1B | ||
| Q2 25 | $399.6M | $1.4B | ||
| Q1 25 | $360.3M | $1.7B | ||
| Q4 24 | $345.0M | $2.0B | ||
| Q3 24 | $445.6M | $1.7B | ||
| Q2 24 | $406.5M | $1.6B | ||
| Q1 24 | $400.3M | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $1.9B | — |
| Q4 25 | $3.8B | $3.3B | ||
| Q3 25 | $3.7B | $5.4B | ||
| Q2 25 | $3.5B | $5.0B | ||
| Q1 25 | $3.3B | $4.7B | ||
| Q4 24 | $3.3B | $4.8B | ||
| Q3 24 | $3.2B | $5.2B | ||
| Q2 24 | $3.1B | $5.0B | ||
| Q1 24 | $2.9B | $5.1B |
| Q4 25 | $8.2B | $15.5B | ||
| Q3 25 | $7.5B | $15.2B | ||
| Q2 25 | $7.1B | $14.5B | ||
| Q1 25 | $6.9B | $14.1B | ||
| Q4 24 | $6.7B | $14.2B | ||
| Q3 24 | $6.9B | $14.4B | ||
| Q2 24 | $6.9B | $14.2B | ||
| Q1 24 | $6.9B | $14.3B |
| Q4 25 | — | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.44× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.65× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $447.5M | $893.0M |
| Free Cash FlowOCF − Capex | $388.8M | $732.0M |
| FCF MarginFCF / Revenue | 26.0% | 30.7% |
| Capex IntensityCapex / Revenue | 3.9% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.06× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $874.7M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $447.5M | $893.0M | ||
| Q3 25 | $284.3M | $938.0M | ||
| Q2 25 | $260.6M | $486.0M | ||
| Q1 25 | $37.4M | $587.0M | ||
| Q4 24 | $432.4M | $905.0M | ||
| Q3 24 | $227.0M | $951.0M | ||
| Q2 24 | $239.6M | $502.0M | ||
| Q1 24 | $92.2M | $595.0M |
| Q4 25 | $388.8M | $732.0M | ||
| Q3 25 | $253.8M | $805.0M | ||
| Q2 25 | $220.7M | $308.0M | ||
| Q1 25 | $11.4M | $438.0M | ||
| Q4 24 | $364.4M | $689.0M | ||
| Q3 24 | $188.8M | $784.0M | ||
| Q2 24 | $205.7M | $370.0M | ||
| Q1 24 | $51.9M | $455.0M |
| Q4 25 | 26.0% | 30.7% | ||
| Q3 25 | 16.9% | 33.5% | ||
| Q2 25 | 14.9% | 12.5% | ||
| Q1 25 | 0.8% | 19.7% | ||
| Q4 24 | 27.3% | 29.7% | ||
| Q3 24 | 13.1% | 32.8% | ||
| Q2 24 | 14.2% | 15.7% | ||
| Q1 24 | 3.7% | 20.8% |
| Q4 25 | 3.9% | 6.7% | ||
| Q3 25 | 2.0% | 5.5% | ||
| Q2 25 | 2.7% | 7.2% | ||
| Q1 25 | 1.9% | 6.7% | ||
| Q4 24 | 5.1% | 9.3% | ||
| Q3 24 | 2.6% | 7.0% | ||
| Q2 24 | 2.3% | 5.6% | ||
| Q1 24 | 2.9% | 6.4% |
| Q4 25 | 2.06× | 1.48× | ||
| Q3 25 | 1.11× | 1.30× | ||
| Q2 25 | 1.07× | 0.68× | ||
| Q1 25 | 0.22× | 0.93× | ||
| Q4 24 | 2.19× | 1.56× | ||
| Q3 24 | 1.03× | 1.39× | ||
| Q2 24 | 1.12× | 0.80× | ||
| Q1 24 | 0.62× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HUBB
| Grid Infrastructure | $717.0M | 48% |
| Industrial | $393.7M | 26% |
| Grid Automation | $218.9M | 15% |
| Electrical Products | $163.1M | 11% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
